NAYA Biosciences Announces Development of NY-500, a Novel AI-Optimized PD-1 x VEGF Bifunctional Antibody
• PD-1 x VEGF antibodies show potential to surpass checkpoint inhibitors as standard-of-care in multiple oncology indications • NAYA aiming...
Cancer
Rakovina Therapeutics Announces Receipt of AI-Derived Drug Candidates and Advancement to Preclinical Validation
VANCOUVER, British Columbia, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV), a biopharmaceutical company focused on the...
Profound Medical to Present at the 43rd Annual J.P. Morgan Healthcare Conference
TORONTO, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device...
Fortress Biotech and Cyprium Therapeutics Announce U.S. FDA Acceptance and Priority Review of NDA for CUTX-101 for Treatment of Menkes Disease
Priority review granted for CUTX-101 with PDUFA target action date set for June 30, 2025 Cyprium is eligible to receive...
Tempest Receives Orphan Drug Designation from the U.S. Food and Drug Administration for Amezalpat to Treat Patients with Hepatocellular Carcinoma (HCC)
BRISBANE, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-class1 targeted...
RAPT Therapeutics Names Lori Lyons-Williams Chair of the Company’s Board of Directors
SOUTH SAN FRANCISCO, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company...
Qu Biologics’ Immunomodulator Improves Fatty Liver Disease
BURNABY, British Columbia, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Qu Biologics Inc., a clinical stage biopharmaceutical company developing Site Specific...
Corbus Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference
NORWOOD, Mass., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced...
Patient Enrolment Completed for INSIGHT-003
Multi-centre trial evaluating efti in combination with pembrolizumab and chemotherapy in patients with non-small cell lung cancer reaches enrolment target...
Beyond Air to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025
GARDEN CITY, N.Y., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a...
Defence Fortifies Patent Portfolio
Vancouver, British Columbia--(Newsfile Corp. - January 6, 2025) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or...
SHOWCASING TOMORROW’S INNOVATORS: LG NOVA RETURNS TO CES 2025
LG NOVA Pushes Forward the Future of Collaboration and Innovation Across Healthtech, AI and Cleantech LAS VEGAS, Jan. 4, 2025...
BriaCell Announces Proposed Effective Date of Share Consolidation
PHILADELPHIA and VANCOUVER, British Columbia, Jan. 03, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell”...
BriaCell Announces Rescheduling of its Annual General Meeting of Shareholders to February 5, 2025
PHILADELPHIA and VANCOUVER, British Columbia, Jan. 03, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell”...
Children’s Hospital of Philadelphia Researchers Develop New Tool with Potential to Advance Precision Medicine Treatment for Cancer
Technology Discovers Antigen-Reactive T Cell Receptors with High Efficiency PHILADELPHIA, Jan. 3, 2025 /PRNewswire/ -- Researchers at Children's Hospital of Philadelphia...
Emerging Specialty EHR Vendors Transform Clinical Workflows With Tailored Solutions, Insights From Black Book Research
54 Specialty EHR Vendors Across 17 Categories Mark New Entries in the 2024 Black Book Surveys with High Satisfaction Marks...
European Patent Office Issues Intention to Grant Notice to IceCure for its Next-Generation Cryoablation Technology
XSense™ system's innovative cryogenic connector technology designed to improve safety and maintain the integrity of cryogen used in the cryoablation procedure...
Cyclacel Pharmaceuticals Announces Agreement for the Acquisition of Preferred Stock by David Lazar
David Lazar agrees to invest $3.1 million in Preferred Stock and becomes Interim CEOBERKELEY HEIGHTS, N.J., Jan. 03, 2025 (GLOBE NEWSWIRE)...
Movano Health Welcomes Dr. Shaheen Wirk to its Board of Directors
PLEASANTON, Calif., Jan. 2, 2025 /PRNewswire/ -- Movano Health (Nasdaq: MOVE), a pioneer in health technology, today announced the expansion of its board...
SELLAS to Host Corporate Update Call on January 8, 2025, at 9:00 am ET
NEW YORK, Jan. 02, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a...